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The production of tissue inhibitor of metalloproteinases (TIMP) in human uterine cervical fibroblasts was increased by human recombinant umor 
necrosis factor a (hrTNF) at a low concentration (0.005 ng/ml) but the elevated synthesis was suppressed in a dose-dependent manner at higher 
concentrations (up to 50 ng/ml). In contrast, the production of collagenase (EC 3.4.24.7) and stromelysin was stimulated at all the corresponding 
concentrations. In contrast, human recombinant interleukin-la (hrIL-1, 10 ng/ml) coordinately induced these enzymes and TIMP production. The 
reduction of the elevated TIMP production by TNF was not due to the inhibition of TIMP secretion. These results suggest hat TNF modulates 
the extracellular matrix degradation in human fibroblasts bifunctionally by the suppression of TIMP production in addition to the acceleration 
of matrix metalloproteinases production. Furthermore, the fact that TNF and IL-l differently controlled the production of TIMP suggests that 
the signal pathway of TNF for TIMP production is different from that of IL-l. 
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1. INTRODUCTION 
Tumor necrosis factor (TNF), a cytokine secreted 
from monocytes in response to immune and inflam- 
matory stimuli or endotoxin, induces the necrosis of 
tumors in vivo and tumor cell killing in vitro [ 11. It also 
exerts other biological effects on the various cell types 
[2,3]. TNF plays a major role in the inflammatory pro- 
cesses by enhancing the destruction of extracellular 
matrix components [4,5], in which matrix metallopro- 
teinases (MMPs), collagenase (MMP-1) and strome- 
lysin (MMP-3) mainly participate [6]. These actions of 
TNF [4,5] are similar to those of another inflammatory 
cytokine interleukin-1 (IL-l) [7,8]. Thus, the in- 
tracellular signal transduction pathway for collagenase 
production by TNF may be analogous to that of IL-l. 
Recently, it is proposed that the advancement of the 
matrix breakdown is caused by the imbalance of 
metalloproteinases and their inhibitor, TIMP [9]. 
However, it is not clearly known how TNF participates 
in the production of TIMP in the connective tissue cells. 
In this paper, we have investigated the effects of 
TNF, in comparison with those of IL-l, on TIMP and 
MMPs production from human fibroblasts. TNF was 
found to modulate bidirectionally the collagenolysis in 
fibroblasts by the acceleration of MMPs production 
and the suppression of TIMP production, whereas IL-l 
accelerated both MMPs and TIMP production coor- 
dinately. 
2. MATERIALS AND METHODS 
Correspondence uddress: A. Ito, Department of Biochemistry, 
Tokyo College of Pharmacy, Horinouchi, Hachioji, Tokyo 192-03, 
Japan 
Abbreviations: TNF, tumor necrosis factor; hrTNF, human recom- 
binant TNFcu, TIMP, tissue inhibitor of metalloproteinases; MMP, 
matrix metalloproteinase; IL-l, interleukin-I; hrIL-1, human recom- 
binant IL-lo; MEM, Eagle’s minimum essential medium; FBS, fetal 
bovine serum; LAH, lactalbumin hydrolysate; SDS-PAGE, sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis 
Eagle’s minimum essential medium (MEM) was purchased from 
Grand Island Biological Co., Grand Island, NY, USA. Fetal bovine 
serum (FBS) was obtained from Whittaker Bioproducts Inc., 
Walkersville, MD, USA. Alkaline phosphatase-conjugated donkey 
anti-(sheep 1gG)IgG and rabbit anti-(mouse IgG)IgG, 5-bromo-4- 
chloro-3-indolyl phosphate, Nitro blue tetrazolium and monensin 
were obtained from Sigma Chemical Co., St. Louis, MO, USA. Pro- 
tein A-Sepharose CL-4B was obtained from Pharmacia LKB, Upp- 
sala, Sweden. L-[‘?S]methionine (800 Ci/mmol) was from American 
Radiolabeled Chemicals, St. Louis, MO, USA. Human recombinant 
TNFcY (hrTNF) (2.55 x lo6 units/mg) and human recombinant IL-lo 
(hrIL-1) (2 x 10’ units/mg) were kindly supplied by Dainippon Phar- 
maceutical Co., Suita, Osaka, Japan. Sheep anti-(human synovial 
procollagenase) and anti-(human synovial stromelysin) antibodies 
were provided by Dr H. Nagase from the University of Kansas 
Medical Center, Kansas City, KS, USA. Mouse monoclonal anti- 
(bovine TIMP)IgG was purchased from Fuji Chemical Industries, 
Tokyo, Japan. Other reagents used were the same as in the previous 
paper 181. 
2.1. Cell culture and treatment 
Human uterine cervical fibroblasts and human chorionic fibro- 
blasts were prepared and maintained in MEM/lO% (v/v) FBS as 
described previously [8]. The confluent cells were treated with hrTNF 
or hrIL-1 in the serum-free MEM containing 0.2% (w/v) lactalbumin 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/90/$3.50 0 1990 Federation of European Biochemical Societies 93 
Volume 269, number 1 FEBS LETTERS August 1990 
hydrolysate (LAH) in order to examine MMPs and TIMP produc- 
tion. 
2.2. Assay for collagenuse activity 
Collagenase was assayed by the fibril assay using [‘4C]acetylated 
collagen as described previously [lo]. Procollagenase in the culture 
medium was activated by treating with 80 ,ug/ml trypsin at 25°C for 
10 min followed by 360 pg/ml excess of soybean trypsin inhibitor 
prior to the assay. One unit of collagenase hydrolyzes 1 gg of 
substrate/min at 37°C. 
2.3. Western blotting 
TIMP, procollagenase and prostromelysin were analyzed by 
Western blotting. The samples were first subjected to SDS-polyacryl- 
amide gel electrophoresis (SDS-PAGE) using 12.5% or 10% acryl- 
amide slab gels [ll] and then proteins were electrotransferred to a 
nitrocellulose filter. Immunoreactive TIMP, procollagenase or pro- 
stromelysin was visualized indirectly by the reaction of 5-bromo- 
4-chloro-3-indolyl phosphate and nitro blue tetrazolium with the 
alkaline phosphatase-conjugated second antibody bound to the 
antigen-antibody complex in the filter as described previously [8]. 
2.4. Labeling with L-P’SJmethionine, immunoprecipitation a d 
fluorography of TIMP 
After treating confluent human uterine cervical fibroblasts with 
hrIL-1 or hrTNF, cells were washed once with methionine-free MEM 
and then incubated with L-[‘sS]methionine (10 &i/ml) in the same 
medium. After a 2 h incubation, medium was collected (medium frac- 
tion). Cells were harvested by scraping with a rubber policeman, 
sonicated in the presence of 1 mM diisopropyl phosphorofluoridate 
and 5 mM EDTA, and centrifuged. Labeled culture media and cell ex- 
tracts were incubated with mouse anti-(bovine TIMP)IgG, and then 
the antigen-antibody complexes were isolated by coupling to protein- 
A Sepharose. Control incubations contained nonimmune mouse IgG 
under the same condition. Immunoprecipitable TIMP was subjected 
to SDS-PAGE and analyzed by fluorography after impregnating the 
gel with EN’HANCE (Dupon, USA) and exposed to Kodak Omat AR 
X-ray film (Eastman Kodak Co.) at - 80°C. 
3. RESULTS AND DISCUSSION 
When human fibroblasts were treated with hrTNF in 
culture, the apparent collagenolytic activity in culture 
media of human chorionic cells increased in a dose- 
dependent manner. Similarly, hrIL-1 enhanced the col- 
lagenolytic activity (Table I). These cytokines also 
stimulated human skin fibroblasts to produce much col- 
lagenolytic activity (data not shown). The collageno- 
lytic activity, however, was not detected with uterine 
cervical fibroblasts even after the treatment of cells with 
hrTNF or hrIL-I. This was due to the similar enhance- 
ment of TIMP production by these cytokines (see 
Fig. 2). Their promotive effects are similar to those 
reported for MMPs production previously [4,5]. Dayer 
et al. [4] reported that TNF stimulates collagenase pro- 
duction from human synovial cells and dermal 
fibroblasts. An increase in gelatinase and collagenase 
production from rat granulation tissue in culture by 
TNF was reported by Nakagawa et al. [5]. However, 
these investigators monitored the production of col- 
lagenase or gelatinase by measuring their enzymic ac- 
tivities in culture media but the amounts of MMPs and 
their inhibitor, TIMP, produced after the TNF treat- 
ment were not examined. In order to understand the 
balance between MMPs and TIMP upon stimulation of 
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Table I 
Effect of hrTNF on the collagenase activity in culture media of 
human fibroblasts 
Treatment Concentration 
(ng/ml) 
Collagenase activity (units/ml) 
Chorionic Cervical 
fibroblasts fibroblasts 
Control 0.04 * 0.03 n.d. 
hrTNF 0.01 0.05 + 0.05 n.d. 
1 0.64 + 0.50 n.d. 
100 1.04 + 0.08+** n.d. 
hrIL-1 10 0.40 f 0.11* n.d. 
Confluent human uterine cervical fibroblasts at eight passage were 
treated with hrTNF or hrIL-1 in 0.2% (w/v) LAH/MEM three times 
for 6 days and human chorionic fibroblasts at fifth passage were 
treated as described above for 2 days. The harvested culture media 
were performed for the assay of collagenase activity. Data are the 
mean value + SD of three wells. 
* and ***; significantly different from control (PcO.05 and 
P<O.OOl, respectively). nd. = not detectable. 
connective tissue cells we examined, using the im- 
munoblotting technique, the amounts of MMPs and 
TIMP proteins produced by the cultured fibroblasts 
following the hrTNF or hrIL-1 treatment. As shown in 
Fig. lA, both hrTNF and hrIL-1 increased the produc- 
tion of procollagenase in the culture media in a dose- 
dependent manner. Similarly, the production of pro- 
stromelysin, which has the ability to degrade various 
connective tissue matrix components [12] and recently 
has been characterized as an endogenous activator for 
procollagenase [ 13,141, was stimulated by these 
cytokines in a dose dependent manner (Fig. 1B). The 
ability of hrTNF or hrIL-1 to induce the production of 
MMPs was also confirmed with human chorionic cells 
(data not shown). In contrast, the effects of hrIL-1 and 
hrTNF on the TIMP production were different from 
each other. As shown in Fig. 2A, hrIL-1 stimulated the 
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Fig. 1. Effect of hrTNF on the production of procollagenase and pro- 
stromelysin from human fibroblasts. Confluent uterine cervical 
fibroblasts at eight passage (A) and sixth passage (B) were treated with 
hrTNF or hrIL-1 in 0.2% (w/v) LAH/MEM for 2 days. The 
harvested culture media (1.5 ml) were mixed with 0.3 ml of 20010 (w/v) 
trichloroacetic acid. The precipitates were collected by centrifugation, 
dissolved in 20 111 of reducing sample buffer and subjected to SDS- 
PAGE. The bands of procollagenase (A) or prostromelysin (B) were 
visualized by immunoblotting as described in section 2. (A) Lane 1, no 
treatment; lanes 2-4, hrlL-1 (0.001, 0.1 and 10 ng/ml, respectively); 
lanes 5-7, hrTNF (0.005,0.5 and 50 ng/ml, respectively). (B) Lane 1, 
no treatment; lanes 2-4, hrTNF (100, 10 and 1 n&ml, respectively); 
lane 5, hrIL-1 (10 ng/ml). 
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Fig. 2. Effect of hrTNF on TIMP production by human fibroblasts. 
ConIluent uterine cervical ~broblasts at eight passage (A) and 
chorionic cells at eighth passage (B) were treated with hrTNF or 
hrIL-1 for 2 days. The harvested culture media were subjected to the 
immunoblotting for TIMP as described in Fig. 1. (A) (10% 
acrylamide gel): lane 1, no treatment; lanes 2-4, hrIL-1 (0.001, 0.1 
and 10 ng/ml, respectively); lanes 5-7, hrTNF (0.005, 0.5 and 50 
ng/mI, respectively). (B) 12.5% acryiamide gel): lane 1, no treatment, 
lanes 2-4, hrTNF (0.01, 1 and 100 nglml, respectively); lanes 5 and 
6, hrIL-1 (1 and 10 ng/ml, respectively). 
production of TIMP from uterine cervical fibroblasts, 
whereas the effects of hrTNF on these cells were 
biphasic; at a low concentration (0.005 nglml, lane 5) 
of TNF early enhanced the production of TIMP, but at 
high concentrations of hrTNF (up to 50 ng/ml) as high 
levels of TNFo in synovial fluids of RA [15] the increas- 
ed TIMP production was reduced in a dose-dependent 
manner. It is unclear why TNF biphasically regulates 
the TIMP production in uterine cervical cells. In con- 
trast, hrTNF consistently suppressed the TIMP produc- 
tion in human chorionic fibroblasts as shown in 
Fig. 2B. These results indicate that hrTNF differential- 
ly regulates the TIMP and MMPs production in human 
fibroblasts. Thus, the hrTNF-enhanced collagenolytic 
activity in culture media is due not only to the increased 
collagenase production but also to the decreased syn- 
thesis of TIMP. 
In order to clarify the mechanism by which the 
decreased TIMP production was caused, we in- 
vestigated the influence of hrTNF on the TIMP secre- 
tion. After the treatment of uterine cervical fibroblasts 
with hrTNF (0.1 or 100 ng/ml) for 24 h, cells were in- 
cubated with L-[35S]methionine in methionine-free 
MEM for 2 h, and immunoreactive %-labeled TIMP in 
both media and cell extracts were analyzed by SDS- 
PAGE followed by fluorography. As shown in Fig. 3, 
a low concentration (0.1 ng/ml) of hrTNF signi~~ntly 
increased TIMP production (lane 3) as well as hrIL-1 
(lane 2). However, at a higher concentration of hrTNF 
(100 ng/ml, lane 4) the synthesis of TIMP was 
significantly suppressed as well as Western blotting 
analysis (Fig. 3, Medium). The decrease in 35S-labeled 
TIMP in the medium was not due to the inhibition of 
TIMP secretion as the intracellular levels of 35S-labeled 
TIMP were indistinguishabie xcept for the cells with 
monensin treatment. These results suggest that TNF 
regulates the TIMP synthesis either at the transcrip- 
tional and/or translation level. 
In conclusion, this is the first report that TNF affects 
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Fig. 3. Effect of hrTNF on the secretion of [3sS]methionine-labeled 
TIMP from human uterine cervical fibroblasts. Fibroblasts at sixth 
passage were preincubated with hrTNF (0.1 or 100 ng/ml) for 24 h 
and then labeled with [%]methionine for 2 h. The harvested culture 
media and cell extracts were subjected to immunoprecipitation, SDS- 
PAGE and fluorography as described in section 2. Lane 1, no treat- 
ment; Iane 2, hrIL-1 (100 ngfml); lanes 3 and 4, hrTNF (0.1 and 100 
ng/ml, respectively); lane 5, hrIL-1 (100 &ml) plus monensin (10 
FM); lane 6, hrIL-1 (100 ng/ml) precipitated using nonimmune IgG. 
the TIMP synthesis from human fibroblasts. Thus TNF 
fifunctionally regulates the collagenolysis in fibroblasts 
by the suppression of TIMP production in addition to 
the acceleration of matrix metalloproteinases produc- 
tion. This is an actual observation since the advanced 
collagenolysis in connective tissue are considered to 
result from the imbalance of MMPs and TIMP [9]. 
Therefore, TNF may play an important role in 
pathological and physiological destruction of connec- 
tive tissue components as well as IL-l. 
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